Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1NET 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1Breast 1

Conditions

Carcinoma, Renal Cell 5Sarcoma 2Prostatic Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Fallopian Tube Neoplasms 2Vulvar Neoplasms 1Recurrence 1Neuroendocrine Tumors 1Neoplasms 1Liver Neoplasms 1Glioblastoma 1Gastrointestinal Neoplasms 1Gallbladder Neoplasms 1Disease 1Colorectal Neoplasms 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Neuroendocrine 1Breast Neoplasms 1Bile Duct Neoplasms 1Advanced Adult Hepatocellular Carcinoma 1

Interventions

Gemcitabine 24Cisplatin 14Capecitabine 12Oxaliplatin 11Fluorouracil 11Leucovorin 7Irinotecan 7Radiotherapy 5durvalumab 4Photochemotherapy 3Magnetic Resonance Spectroscopy 3Long-Term Synaptic Depression 3Erlotinib Hydrochloride 3Cholangiopancreatography, Endoscopic Retrograde 3Carboplatin 3trifluridine tipiracil drug combination 2regorafenib 2olaparib 2ceralasertib 2Stents 2Sorafenib 2Radiosurgery 2Radiofrequency Ablation 2Liver Transplantation 2Filgrastim 2Dihematoporphyrin Ether 21-phenyl-3,3-dimethyltriazene 2zimberelimab 1tivozanib 1titanium silicide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Bile Duct Neoplasms × tivozanib × Clear all
NCT05000294 2026-06-05

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

Phase 1/2 Recruiting
29 enrolled
BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡